Results 11 to 20 of about 74,566 (254)

Unlocking the potential of approved drugs for the allosteric inhibition of tropomyosin-receptor kinase A using molecular docking and molecular dynamics studies [PDF]

Frontiers in Chemistry, 2023
Tropomyosin-receptor kinase A (TrkA) is the primary isoform among the tropomyosin-receptor kinases that have been associated with human cancer development, contributing to approximately 7.4% of all cancer cases.
Rua M. Mukhtar, Nihal Abdelmoniem, Hisham A. Elrufaie, Alaa Edris, Hiba Ghaboosh, Mohanad A. Mahgoub, Elrashied A. E. Garelnabi, Wadah Osman, Wadah Osman, Asmaa E. Sherif, Asmaa E. Sherif, Ahmed Ashour, Ahmed Ashour, Kholoud F. Ghazawi, Waad A. Samman, Aisha A. Alhaddad, Rawan Bafail, Sabrin R. M. Ibrahim, Sabrin R. M. Ibrahim, Gamal A. Mohamed, Abdulrahim A. Alzain   +20 more
doaj   +3 more sources

Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors—Synthetic Strategies and SAR Insights [PDF]

Molecules
Tropomyosin receptor kinases (Trks) are transmembrane receptor tyrosine kinases named TrkA, TrkB, and TrkC and encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively.
Amol T. Mahajan, Shivani, Ashok Kumar Datusalia, Carmine Coluccini, Paolo Coghi, Sandeep Chaudhary   +5 more
doaj   +5 more sources

Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours [PDF]

The Journal of Pathology: Clinical Research, 2023
Tropomyosin receptor kinase B (TrkB), a transmembrane receptor protein, has been found to play a pivotal role in neural development. This protein is encoded by the neurotrophic receptor tyrosine kinase 2 (NTRK2) gene, and its abnormal activation caused ...
Yuehua Li, Chengjiang Wei, Wei Wang, Qingfeng Li, Zhi‐Chao Wang   +4 more
doaj   +3 more sources

Regulation of Eosinophil Recruitment and Allergic Airway Inflammation by Tropomyosin Receptor Kinase A. [PDF]

J Immunol, 2020
Key Points Eosinophilia is a characteristic feature of allergic airway inflammation and asthma. TrkA activation by eotaxin-1 promotes eosinophil migration and airway inflammation.
Dileepan M, Ge XN, Bastan I, Greenberg YG, Liang Y, Sriramarao P, Rao SP, Rao SP.   +7 more
europepmc   +5 more sources

Sensory Neuron-Specific Deletion of Tropomyosin Receptor Kinase A (TrkA) in Mice Abolishes Osteoarthritis (OA) Pain via NGF/TrkA Intervention of Peripheral Sensitization. [PDF]

Int J Mol Sci, 2022
Tropomyosin receptor kinase A (TrkA/NTRK1) is a high-affinity receptor for nerve growth factor (NGF), a potent pain mediator. NGF/TrkA signaling elevates synovial sensory neuronal distributions in the joints and causes osteoarthritis (OA) pain.
O-Sullivan I, Kc R, Singh G, Das V, Ma K, Li X, Mwale F, Votta-Velis G, Bruce B, Natarajan Anbazhagan A, van Wijnen AJ, Im HJ.   +11 more
europepmc   +2 more sources

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. [PDF]

Cancer, 2023
Larotrectinib, a first‐in‐class, highly selective tropomyosin receptor kinase (TRK) inhibitor, has demonstrated efficacy in adult and pediatric patients with various solid tumors harboring NTRK gene fusions.
Kummar S, Shen L, Hong DS, McDermott R, Keedy VL, Casanova M, Demetri GD, Dowlati A, Melcón SG, Lassen UN, Leyvraz S, Liu T, Moreno V, Patel J, Patil T, Mallick AB, Sousa N, Tahara M, Ziegler DS, Norenberg R, Arvis P, Brega N, Drilon A, Tan DSW.   +23 more
europepmc   +2 more sources

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. [PDF]

JCO Precis Oncol, 2022
PURPOSE Larotrectinib is a highly selective and CNS-active tropomyosin receptor kinase (TRK) inhibitor that has demonstrated efficacy across TRK fusion–positive cancers, regardless of the tumor type.
Drilon A, Tan DSW, Lassen UN, Leyvraz S, Liu Y, Patel JD, Rosen L, Solomon B, Solomon B, Norenberg R, Dima L, Brega N, Shen L, Moreno V, Kummar S, Lin JJ.   +15 more
europepmc   +2 more sources

Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis [PDF]

Arthritis Research & Therapy, 2016
Background: Inflammation is an essential component of arthritis pain. Nerve growth factor (NGF) plays a key role in acute and chronic pain states especially those associated with inflammation. NGF acts through tropomyosin-receptor-kinase A (TrkA).
A Bendele, A Bendele, AK Suokas, AM Bendele, B Nico, BG Petty, C Barthel, CD Dijkstra, CJ Woolf, CM Pearson, CS Bonnet, D Male, DA Walsh, DA Walsh, DA Walsh, DA Walsh, David A. Walsh, DL Shelton, DN Benslay, DR Sagar, G Schett, GR Lewin, HC Seegers, HG Schaible, Jed Pheneger, JR Ghilardi, JR Ghilardi, JR Ghilardi, Karyn S. Bouhana, KE McNamee, KM Mearow, KS Williams, L Aloe, L Aloe, L Djouhri, L Manni, LA Stoppiello, LN Nwosu, M Koltzenburg, NE Lane, NH Waseem, P Sanga, PI Mapp, PI Mapp, PI Mapp, PJ Tiseo, PP Sanna, S Ashraf, S Ashraf, S Ashraf, S Ashraf, S Ashraf, S Suri, Sadaf Ashraf, SB McMahon, Steven W. Andrews, TJ Coderre, WO Cooper   +57 more
core   +5 more sources

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers [PDF]

Acta Pharmaceutica Sinica B, 2021
Tropomyosin receptor kinase A, B and C (TRKA, TRKB and TRKC), which are well-known members of the cell surface receptor tyrosine kinase (RTK) family, are encoded by the neurotrophic receptor tyrosine kinase 1, 2 and 3 (NTRK1, NTRK2 and NTRK3) genes ...
Tingting Jiang, Guan Wang, Yao Liu, Lu Feng, Meng Wang, Jie Liu, Yi Chen, Liang Ouyang   +7 more
doaj   +2 more sources

Synthetic inhibitor leads of human tropomyosin receptor kinase A (hTrkA). [PDF]

RSC Medicinal Chemistry, 2020
In silico virtual screening followed by in vitro biochemical, biophysical, and cellular screening resulted in the identification of distinctly different hTrkA kinase domain inhibitor scaffolds. X-ray structural analysis of representative inhibitors bound
G. Subramanian, Rajendran Vairagoundar, Scott J. Bowen, Nicole S Roush, T. Zachary, Christopher Javens, T. Williams, Annette Janssen, A. Gonzales   +8 more
semanticscholar   +3 more sources